Lancet Diabetes Endocrinol:睾酮替代可以改善老年男性的步行能力

2018-11-05 医研荟MedHub 医研荟MedHub

身体功能试验(PhysicalFunction Trail, PFT)是七个睾丸激素试验(Testosterone Trails, TTrials)之一,其目的是在睾酮浓度低,自我报告的活动受限和步行速度小于1.2m / s的老年男性中评估睾丸激素对机动性、自我报告的身体机能、跌倒和患者全球变化(patient global impression-of-change, PGIC)的影响。


背景:身体功能试验(PhysicalFunction Trail, PFT)是七个睾丸激素试验(Testosterone Trails, TTrials)之一,其目的是在睾酮浓度低,自我报告的活动受限和步行速度小于1.2m / s的老年男性中评估睾丸激素对机动性、自我报告的身体机能、跌倒和患者全球变化(patient global impression-of-change, PGIC)的影响。利用来自PFT和总体TTrials研究人群的数据,其目的还旨在确定睾丸激素对流动性的影响是否因基线行走速度,行动限制或其他参与者水平因素的不同而不同。
 
方法:TTrials包含790名65岁或以上的男性,他们的平均睾酮浓度低于275 ng / dL(9.5 nmol / L),其中390人的行动受限,行走速度低于1.2 m/ s,并被纳入PFT。参与者被分为1%的睾丸素凝胶或安慰剂凝胶,为期12个月,参与者和研究人员蒙面干预分配。PFT的主要结果是增加6分钟步行测试距离(6 min walktest, 6MWT)50米或以上。
 
结果:TTrials于2011年4月28日至2014年6月16日期间进行。在790名TTrials参与者中,395名分配了睾丸激素,395名分配了安慰剂; 在参加PFT的390名参与者中,193名被分配到睾丸激素,197名被分配到安慰剂。如前所述,在TTrials的所有男性中,睾丸激素组的6分钟步行测试距离显著高于安慰剂组,但在那些参加PFT的人中则没有增加; 在没有参加PFT的TTrials参与者中,6分钟步行测试距离得到改善,增加了8.9米。如前所述,在TTrials和参加PFT的男性中,PF10在睾丸激素组中比在安慰剂组中改善更多; 在未参加PFT的人群中,PF10的效应量为4.0。对比安慰剂组,接受睾丸激素组的男性的6分钟步行测试距离有显著改善,其基线行走速度为1.2 m / s或更高(治疗效果为14.2 m)和PF10(4.9)。对比安慰剂组,睾丸激素组的男性其自我报告活动受限的6分钟步行测试距离显著提高(7.6 m),PF10(3.6)。睾丸激素组的男性比安慰剂组的男性更容易察觉到他们步行能力的提高,包括参加 PFT 的男性(效应量为2.21)和未参加PFT的男性(3.01)。6分钟步行测试距离的变化与睾丸素,游离睾丸素,二氢睾丸素,和血红蛋白浓度的变化显著相关。干预期间的跌倒频率在TTrials的两个治疗组中是相同的(在两组中分析的380例中有103例[27%]至少有一次跌倒)。
 
结论:睾丸素治疗可以持续改善自我报告的步行能力,适度改善6分钟步行距离(包括所有TTtrials的参与者),但对跌倒没有影响。睾丸素对移动性测量的影响与基线步态速度和自我报告的移动性限制以及睾酮和血红蛋白浓度的变化有关。



版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1638842, encodeId=d5cf16388421f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 24 00:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654828, encodeId=b81f1654828d3, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Fri Jul 26 12:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760881, encodeId=db7d1e6088175, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Sep 24 12:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902159, encodeId=7f92190215935, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 17 15:04:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897813, encodeId=d8d0189e81340, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 02 04:04:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829872, encodeId=147c18298e24f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 09:04:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1638842, encodeId=d5cf16388421f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 24 00:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654828, encodeId=b81f1654828d3, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Fri Jul 26 12:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760881, encodeId=db7d1e6088175, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Sep 24 12:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902159, encodeId=7f92190215935, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 17 15:04:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897813, encodeId=d8d0189e81340, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 02 04:04:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829872, encodeId=147c18298e24f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 09:04:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
    2019-07-26 yuanming15
  3. [GetPortalCommentsPageByObjectIdResponse(id=1638842, encodeId=d5cf16388421f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 24 00:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654828, encodeId=b81f1654828d3, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Fri Jul 26 12:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760881, encodeId=db7d1e6088175, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Sep 24 12:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902159, encodeId=7f92190215935, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 17 15:04:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897813, encodeId=d8d0189e81340, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 02 04:04:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829872, encodeId=147c18298e24f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 09:04:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1638842, encodeId=d5cf16388421f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 24 00:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654828, encodeId=b81f1654828d3, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Fri Jul 26 12:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760881, encodeId=db7d1e6088175, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Sep 24 12:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902159, encodeId=7f92190215935, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 17 15:04:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897813, encodeId=d8d0189e81340, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 02 04:04:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829872, encodeId=147c18298e24f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 09:04:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1638842, encodeId=d5cf16388421f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 24 00:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654828, encodeId=b81f1654828d3, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Fri Jul 26 12:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760881, encodeId=db7d1e6088175, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Sep 24 12:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902159, encodeId=7f92190215935, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 17 15:04:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897813, encodeId=d8d0189e81340, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 02 04:04:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829872, encodeId=147c18298e24f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 09:04:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1638842, encodeId=d5cf16388421f, content=<a href='/topic/show?id=afda591646' target=_blank style='color:#2F92EE;'>#DIA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5916, encryptionId=afda591646, topicName=DIA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=987022654425, createdName=ms9608593228839890, createdTime=Tue Sep 24 00:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1654828, encodeId=b81f1654828d3, content=<a href='/topic/show?id=4eb6632899b' target=_blank style='color:#2F92EE;'>#步行#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63289, encryptionId=4eb6632899b, topicName=步行)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6a5524567114, createdName=yuanming15, createdTime=Fri Jul 26 12:04:00 CST 2019, time=2019-07-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1760881, encodeId=db7d1e6088175, content=<a href='/topic/show?id=9bea33520d' target=_blank style='color:#2F92EE;'>#BET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3352, encryptionId=9bea33520d, topicName=BET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a1a37427546, createdName=ms5439512287675881, createdTime=Tue Sep 24 12:04:00 CST 2019, time=2019-09-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1902159, encodeId=7f92190215935, content=<a href='/topic/show?id=c097591ed5' target=_blank style='color:#2F92EE;'>#Diabetes#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5917, encryptionId=c097591ed5, topicName=Diabetes)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0045169, createdName=木头人513, createdTime=Sun Feb 17 15:04:00 CST 2019, time=2019-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1897813, encodeId=d8d0189e81340, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Sun Dec 02 04:04:00 CST 2018, time=2018-12-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829872, encodeId=147c18298e24f, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Dec 07 09:04:00 CST 2018, time=2018-12-07, status=1, ipAttribution=)]
    2018-12-07 howi

相关资讯

Cell Metab:上海交通大学揭示脂肪组织在高血压心脏重塑的分子调控过程

2018年7月12号,上海交通大学医学院附属瑞金医院高平进课题组等人在Cell子刊Cell Metabolism上在线发表了题为“A2A Receptor Activation Attenuates Hypertensive Cardiac Remodeling via Promoting Brown Adipose Tissue-Derived FGF21”的研究论文。研究人员发现腺苷A2A受体

Bone Res:科学家发表骨代谢综述文章

近期,国际学术期刊Bone Research在线发表了中国科学院生物化学与细胞生物学研究所邹卫国研究组的综述文章Paracrine and endocrine actions of bone-the functions of secretory proteins from osteoblasts, osteocytes, and osteoclasts。该文章系统阐述了成骨细胞、骨细胞和破骨细胞分

金锋教授、胡夕春教授解析如何全方位探讨乳腺癌内分泌治疗策略

第十三届上海国际乳腺癌论坛(SIBCS)顺利召开。内分泌治疗作为乳腺癌的一大治疗策略,在本届SIBCS上也是众多医学同道中的热议话题。有幸邀请中国医科大学附属第一医院的金锋教授和复旦大学附属肿瘤医院的胡夕春教授共同对话,一起聊聊关于乳腺癌内分泌治疗的思考与体会。

JAMA Network Open:年轻癌症幸存者内分泌患病风险增高

导语 青少年和年轻成年癌症幸存者的内分泌疾病风险比无癌人群高73%。

胃神经内分泌肿瘤1例

女,64岁,三个月来黑便三次,无其他不适,CA199略高29.36(0-27)

CSCO2018大家访谈录│王晓稼教授:内分泌+CDK4/6抑制剂还是化疗

9月21日下午,2018CSCO举行了“CSCO 乳腺癌专家委员会-乳腺癌内分泌治疗专场”,诸位大咖针对乳腺癌内分泌治疗进行了不同方面的探讨。浙江省肿瘤医院王晓稼教授作专题报告“晚期乳腺癌治疗策略:内分泌联合CDK4/6抑制剂还是化疗”。